Ketotifen
Brand names: Zaditen
Ketotifen is an antihistamine with mast cell stabilising properties used as eye drops for the treatment of seasonal allergic conjunctivitis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It blocks histamine H1 receptors and stabilises mast cells to reduce the release of inflammatory mediators, relieving the itching, redness and watering of allergic conjunctivitis.
Prescribing in practice
- Preservatives such as benzalkonium chloride in some formulations can be absorbed by soft contact lenses and cause ocular irritation, so lenses should be removed before instillation and reinserted only after a suitable interval.
- Transient stinging or burning and, rarely, mild drowsiness may occur.
- Used for symptomatic relief of allergic conjunctivitis and is generally well tolerated for seasonal use.
Monitoring
No systemic monitoring is required; review symptom control clinically and reassess if symptoms persist or worsen.
Counselling the patient
- Remove soft contact lenses before instilling and wait the recommended interval before reinserting them.
- Brief blurring or stinging may occur after instillation, so wait until vision clears before driving.
Evidence & guidelines
Topical antihistamine and mast cell stabilising drops are recommended for allergic conjunctivitis in NICE Clinical Knowledge Summaries.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Urticaria Activity Score (UAS7) · Urticaria
- C-Peptide to Glucose Ratio · Diabetes Classification
- IMDC (Heng) Score for Metastatic RCC · Renal Cell Carcinoma
- International Prognostic Index (IPI) for DLBCL · Lymphoma
- IMDC Risk Model for Metastatic Renal Cell Carcinoma · Cancer Prognosis
- HCT-CI — Haematopoietic Cell Transplant Comorbidity Index · Risk Stratification
- Acute Red Eye / Vision Loss Screen · RCOphth 2020; NICE CKS
- Idiopathic Intracranial Hypertension · ABN; consensus 2018
- Acute Red Eye Assessment · RCOphth / AAO
- Acute Angle Closure Glaucoma · RCOphth / EGS Guidelines
- Retinal Detachment · RCOphth Guidelines / EURETINA
- Diabetic Retinopathy — Screening and Management · NICE NG28 2016 / NHS DES Programme